What the Consolidated Appropriations Act of 2026 May Mean for Health Plans and Pharmacy Benefit Oversight
For years, PBM transparency has been debated across policy panels, consultant reports, and contract negotiations.
What may be changing now is where that conversation actually lives.
Recent federal action suggests that rebate economics, long treated as a background contract detail, may increasingly become part of the formal governance workflow for group health plans.
The Consolidated Appropriations Act of 2026, signed earlier this year, introduced provisions affecting how pharmacy benefit managers disclose compensation and rebate-related financial flows to group health plans and their fiduciaries. At the same time, the U.S. Department of Labor has been advancing rulemaking aimed at improving transparency into PBM compensation and fees under ERISA.
Taken together, these developments signal a broader push toward clearer financial visibility in the pharmacy benefit ecosystem.
For plan sponsors, TPAs, and advisors, the implication is subtle but important:
Rebate transparency may be shifting from a “best practice” conversation to a fiduciary workflow.
A Governance Shift
The recent policy developments do not fundamentally change how manufacturer rebates work overnight.
Instead, they focus on something different: documentation, disclosure, and oversight.
For years, rebate economics have largely been handled through contracts and vendor reporting. The new regulatory focus suggests that these financial mechanics may increasingly fall within plan fiduciaries’ formal oversight responsibilities.
In practical terms, the direction of travel appears clear:
- PBM compensation structures are receiving greater scrutiny
- Group health plan fiduciaries are expected to have clearer visibility into rebate flows and related fees
- Reporting expectations around pharmacy benefit arrangements are expanding
While none of these ideas are entirely new, taken together they point to a broader shift.
Drug-benefit economics are moving closer to the governance processes that health plans already apply to other major vendors and financial arrangements.
Why This Matters Operationally
The immediate impact of these developments may not show up in pharmacy pricing.
Instead, the first shift many organizations may feel is how rebate economics are reviewed and validated.
As transparency expectations evolve, several practical questions may become more important for plan sponsors and their advisors:
- Can rebate flows be clearly traced from manufacturer agreements to plan-level reporting?
- Do PBM contracts make compensation structures easy to understand?
- Are reconciliation processes structured in a way that can withstand fiduciary review?
Many organizations already examine these questions today.
However, as disclosure requirements evolve, the difference between having rebate visibility and having rebate documentation that holds up to scrutiny may become increasingly important.
What to Watch
The regulatory environment surrounding PBMs continues to evolve, and implementation details will likely develop over time.
Recent developments include the Department of Labor’s proposed rule aimed at improving transparency into PBM compensation and fee arrangements under ERISA. Following the passage of the Consolidated Appropriations Act of 2026, the Department of Labor also extended the public comment period on the proposed rule to allow stakeholders to address the law’s new provisions affecting PBM disclosures.
These developments suggest that the market may place greater emphasis on:
- clearer documentation of PBM compensation structures
- more standardized reporting around pharmacy benefit economics
- stronger expectations that plan fiduciaries understand the financial mechanics of their pharmacy benefit arrangements
For many organizations, the practical first step may not involve changing vendors or renegotiating contracts.
Instead, it may simply involve ensuring that rebate reporting and compensation structures are transparent enough to review, explain, and validate.
The Bottom Line
Policy debates about PBM transparency have been ongoing for years.
What may be changing now is where those conversations take place.
As new reporting and disclosure expectations emerge, pharmacy benefit economics may move closer to the core governance responsibilities of group health plan fiduciaries.
In that environment, clarity around rebate flows, compensation structures, and financial reporting may become less of a negotiation point and more of a baseline expectation.
Sources
U.S. Department of Labor – Improving Transparency into Pharmacy Benefit Manager Compensation and Fees (Proposed Rule)
https://public-inspection.federalregister.gov/2026-01907.pdf
U.S. Department of Labor – Extension of Comment Period Following the Consolidated Appropriations Act of 2026
https://www.federalregister.gov/documents/2026/03/02/2026-04084/improving-transparency-into-pharmacy-benefit-manager-fee-disclosure-extension-of-comment-period
Morgan Lewis – The New Landscape of PBM Fiduciary Oversight Under the Consolidated Appropriations Act of 2026
https://www.morganlewis.com/pubs/2026/02/consolidated-appropriations-act-of-2026-the-new-landscape-of-pbm-fiduciary-oversight
Groom Law Group – Drug Pricing and Plan Contracting Practices Under Scrutiny
https://www.groom.com/resources/drug-pricing-and-plan-contracting-practices-under-scrutiny-pbm-and-tpa-reforms-in-the-consolidated-appropriations-act-2026/
Kaiser Family Foundation – What to Know About Pharmacy Benefit Managers and Federal Efforts at Regulation
https://www.kff.org/other-health/what-to-know-about-pharmacy-benefit-managers-pbms-and-federal-efforts-at-regulation/
Disclaimer: This edition of The Rebate Report is intended for general informational purposes only and reflects publicly available information and market observations. It should not be construed as legal, regulatory, or fiduciary advice. Organizations should consult appropriate legal and benefits advisors when evaluating pharmacy benefit arrangements or regulatory obligations.
